Vanta Bioscience (BOM:540729) EBIT: ₹6.32 Mil (TTM As of Mar. 2026)


BOM:540729 Vanta Bioscience Ltd BOM:540729
56 GF Score
Price ₹25.29
GF Value ₹12.07
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Vanta Bioscience EBIT?

Vanta Bioscience BOM:540729 +4.98% 56 EBIT is ₹6.32 Mil as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 56/100 and a GF Value™ of ₹12.07 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Vanta Bioscience's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹16.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vanta Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 was 5.31%. Vanta Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vanta Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.13%.

Vanta Bioscience  (BOM:540729) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vanta Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=32.3 * ( 1 - 0% )/( (573.235 + 643.583)/ 2 )
=32.3/608.409
=5.31 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=568.642 - 23.027 - ( 1.477 - max(0, 139.128 - 111.508+1.477))
=573.235

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=661.026 - 16.089 - ( 1.354 - max(0, 118.212 - 141.321+1.354))
=643.583

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Vanta Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=32.3/( ( (102.829 + max(37.054, 0)) + (96.769 + max(56.685, 0)) )/ 2 )
=32.3/( ( 139.883 + 153.454 )/ 2 )
=32.3/146.6685
=22.02 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18.169 + 77.309 + 5.061) - (23.027 + 0 + 40.458)
=37.054

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.584 + 75.275 + 5.332) - (16.089 + 0 + 33.417)
=56.685

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vanta Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=6.315/559.290
=1.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience EBIT Related Terms

Vanta Bioscience EBIT Historical Data

* Premium members only.

The historical data trend for Vanta Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience EBIT Chart

Vanta Bioscience Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.40 -46.58 -31.03 -20.68 7.91

Vanta Bioscience Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.53 -20.32 -15.05 -9.84 16.15

BOM:540729 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Vanta Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanta Bioscience EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vanta Bioscience's EV-to-EBIT falls into.


BOM:540729
56GF Score
Vanta Bioscience Ltd BOM:540729
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanta Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹6.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹6.32 Mil mean?
Vanta Bioscience (BOM:540729) has a EBIT of ₹6.32 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vanta Bioscience.
Is Vanta Bioscience's EBIT too high?
Vanta Bioscience's current EBIT is ₹6.32 Mil. Overall, Vanta Bioscience has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's EBIT compare to TMO and DHR?
Vanta Bioscience's EBIT of ₹6.32 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vanta Bioscience. Vanta Bioscience's current EBIT is ₹6.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.07, compared to a current price of ₹25.29 — trading 109.5% above its estimated fair value. The current EBIT is ₹6.32 Mil. Vanta Bioscience's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current EBIT is ₹6.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹25.29 is trading 109.5% above its estimated GF Value™ of ₹12.07. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • EBIT: ₹6.32 Mil
  • GF Value™: ₹12.07 vs. price of ₹25.29 (109.5% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
56GF Score

Get the complete analysis for BOM:540729

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.29
Price
₹12.07
GF Value